The 13G filing shows that John Markey has a 9.9% passive stake in T2 Biosystems. This indicates that he is not actively involved in the company's decision-making process. The news may not have a significant short-term impact on the stock price, as passive stakes are generally considered less influential than active stakes. However, it does show that a notable investor has confidence in the company, which could have a positive long-term effect.